anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Excessive weight gain during pregnancy is predictive of a host of health outcomes in both the mother and child, particularly among women who are overweight or obese pre-pregnancy. Gaining too much weight is associated with higher risk of gestational diabetes, large birth weight for the baby and its corresponding risks, and postpartum obesity. Alarmingly, these outcomes persist for years after birth. For adults who are overweight or obese and interested in weight management, a key element of behavioral weight control is self-monitoring. Supported by self-regulation theory, the effectiveness of daily weighing is likely a function of the self-regulatory processes that are activated as a result of this behavior. Receiving feedback daily on weight proximal to diet and exercise behaviors may increase awareness how of behaviors impact weight and allow for small changes in weight to be understood and resolved through subsequent behavior change. Given the improvements in self-regulation as a result of daily weighing, it may be an effective strategy for reducing excessive gestational weight gain during pregnancy. It is not clear, however, whether pregnant women would engage in this behavior and whether daily weighing would be effective in promoting recommended levels of weight gain during pregnancy.

To determine the feasibility of a six-week, digital health daily weighing pilot intervention to monitor gestational weight gain among overweight and obese pregnant women, participants will be recruited at up to 20 weeks' gestation (consistent with prior studies) and will receive a digital wireless Bluetooth-enabled scale to track weight for six weeks during pregnancy. They will receive tailored feedback via weekly emails in response to adherence to daily weighing and whether weight gains are in accordance with recommended levels and healthy standards for pregnancy; weekly emails will also communicate healthy eating and physical activity tips for pregnancy. They will be asked to complete surveys at baseline (before using scales) and follow-up (after using scales) that focus on experiences with weight monitoring, GWG knowledge and expectations, and perceptions of the intervention process.
A process for the production and screening of materials for use in pharmaceutical aerosol formulations, and the subsequent manipulation of particle clouds and drug morphology, comprises the following key steps:- <SL> <LI>(a) Formation of a solution of a pharmaceutical acceptable substance (or mixture of substances) in a suitable solvent (or mixture of solvents and excipients), <LI>(b) Formation of a derivative (eg salt) that has enhanced solubility in said solvent(s), <LI>(e) Manipulation of reactants and anti-solvent(s) to precipitate said derivative(s) (so that it can be subsequently utilised as a formulation in its own right, e.g. in-situ precipitation into an aerosol container), <LI>(f) Removal of reactant and isolation of derivatives(s) from (e) to produce particles (suitable for use in alternative dosage form or to be returned into the initial dosage form at a later date) <LI>(g) Manipulation of the morphology and particle size of the acceptable substance(s) to be delivered from the dosage form. </SL> In the examples, salbutamol base is mixed with maleic or oleic acid in a solvent, dissolved with heating to give a solution of the corresponding, then chilled to cause the salt to precipiatate. Also claimed are :- <DL TSIZE=2> <DT>-<DD>A combination formulation of drugs of varying receptor category (e.g. bronchodilator and steroid), especially a ```derivative formed from the reaction between two suitable actives forming an adduct (e.g. salbutamol and cromoglycic acid forming salbutamol cromoglycate). <DT>-<DD>A process whereby the particle size distribution of a pressurised metered dose aerosol formulation is of a distribution similar to a suspension formulation without excessive non-volatile excipients, (especially a <DT>-<DD>process whereby the use of increased ethanol/water co-solvents in a solution formulation modifies the particle size distribution further). - The use of a salt medicament to alter the particle size of a pressurised metered dose aerosol formulation solution. <DT>-<DD>The use of a salt derivative formed from a surface-active agent enabling a change in particle morphology post aerosolisation to spread over a tissue surface. <DT>-<DD>The use of temperature and humidity of intake air to reduce actuator and throat deposition from metered dose inhalers. <DT>-<DD>The use of a derivative that negates the adverse effects of temperature and humidity of physiologic conditions maintaining constant fine particle dose deposition from metered dose inhalers. </DL>
Group 3 innate lymphoid cells (ILC3s) are important for maintaining gut homeostasis. Upon stimulation, ILC3s can rapidly produce cytokines to protect against infections and colitis. However, the regulation of ILC3 quick response is still unclear. Here, we find that eIF6 aggregates with Nsun2 and cytokine mRNA in ILC3s at steady state, which inhibits the methyltransferase activity of Nsun2 and the nuclear export of cytokine mRNA, resulting in the nuclear reservation of cytokine mRNA. Upon stimulation, phosphorylated p38α phosphorylates eIF6, which in turn releases Nsun2 activity, and promotes the nuclear export of cytokine mRNA and rapid cytokine production. Genetic disruption of p38α, Nsun2, or eIF6 in ILC3s influences the mRNA nuclear export and protein expression of the protective cytokines, thus leading to increased susceptibility to colitis. Together, our data identify a crucial role of the p38α-eIF6-Nsun2 axis in regulating rapid ILC3 immune response at the posttranscriptional level, which is critical for gut homeostasis maintenance and protection against gut inflammation.
PURPOSE: Placenta-mediated pregnancy complications, like growth restriction and hypertensive disorders, are leading causes of maternal, fetal and neonatal morbidity and mortality in high-income countries. The purpose was to investigate if there is a seasonal variation in placenta-mediated pregnancy complications (small for gestational age, intrauterine growth restriction, preeclampsia, preterm birth and intrauterine fetal death).
METHODS: This is a Danish cohort study including all singleton deliveries at gestational week 22 up to and including week 41 conceived from December 2006 to November 2016 (N = 555,459). We used statistical process control charts to visualize data and to test for patterns of non-random variation in data over time for pregnancies with risk factors (BMI, diabetes, in vitro fertilization, maternal age > 40 years, primipara, previous caesarean and smoking) and each of the following outcome: fetal growth restriction, hypertensive disorders, preterm birth and intrauterine fetal death. The study was approved by the Danish Data Protection agency; REG-039-2019.
RESULTS: We found a seasonal pattern in hypertensive disorders during pregnancy with dips in pregnancies conceived in the fall season and highest risk by conception in the spring and summer season. We found no apparent seasonality in cases of preterm delivery, small for gestational age and intrauterine mortality. Individual risk factors (e.g. smoking and obesity) for placenta-mediated complicated over time were in consistency with the general trends.
CONCLUSIONS: We found a significant seasonal variation in the risk of hypertensive disorders of pregnancy with highest risk by conception in the spring and summer season. This study found no seasonal variation in other placenta-mediated complications.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes the combined preparation "XYMEZOLONE" for treatment of patients with osteoarthrosis containing the following components per each dosing unit, mg: xymedone, 20-30; prednizolon, 2.0-3.0 as active components; starch, 4- 5; talc, 0.1-0.2 as excipients. Method for treatment of patients with osteoarthrosis involves administration of curative dose of xymezolone orally, 4-6 times per a 24 h for 4-5 days and then by 1-2 times per 24 h, treatment course is 2-3 weeks and repeated 1-3 courses with interval for 20-30 days between courses. The novel combined preparation expands assortment of curative drugs, allows reducing frequency of complications rise and adverse effects in retention of high curative effectiveness. EFFECT: enhanced effectiveness, valuable medicinal properties of preparation. 3 cl, 3 tbl
The invention provides a single-component hair dye using light energy, the hair dye would not damage skin and hair, and is comparative stable. The hair dye is prepared by adding silver salts of 0.3%-5.0% by weight (wherein silver halide is not contained) and amino acid of 0.2%-5.0% by weight (wherein reducible amino acid such as cysteine or the like, and sulfur-containing amino acid such as acimetion or the like are not contained). The amino acid preferably is neutral amino acid, acidic amino acid, basic amino acid (wherein reducible amino acid such as sulfur-containing amino acid and cysteine or the like is not contained). Especially preferable amino acid is basic amino acid such as arginine, histidine, lysine, or the like. PH of the preparation can be adjusted to 2-8. Further, 0.01%-1.5% dihydroxyacetone by weight can be added in the hair dye, and the PH of the preparation is adjusted to 2-7.
A sol-gel vault which comprises a complex between a vault particle and a sol-gel. The vault particle comprises one or more one or more passenger molecules. At least one of the one or more passenger molecules is an mINT passenger molecule. At least one of the one or more passenger molecules is a protein. At least one of the one or more passenger molecules is an enzyme. The sol-gel is a silica-based sol-gel.
During marketing of escitalopram and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with escitalopram. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [see Dosage and Administration (2.5)].
PURPOSE: A black rice bran, Basidiomycetes, and a bioconverted product are remarkably improve activation of macrophage and dendritic cells, and to be used as an immunoadjuvant. CONSTITUTION: A method for manufacturing an immunoadjuvant comprises the steps of: making a liquid culture medium using black rice (Oryza sativa L.); inoculating Basidiomycetes to the liquid black rice medium and culturing the strain; and producing a bioconverted product with improved immunity from the culture. The bioconverted product is a polymeric polysaccharide. The effective concentration (EC50) of the immunoadjuvant is 1 microgram/mL or less in measuring activation of macrophage. A physiologically active material with immunity is prepared by the method. A pharmaceutical, a health food, a feed additive, or a cosmetic composition contains the physiologically active material. [Reference numerals] (AA) NO generation amount (abs); (BB) AHCC (Japan); (CC) senseiro (Japan); (DD) Mesima (pharmaceutical product); (EE) Fucoidan (high purity polymeric immunopolysaccharide); (FF) Black rice bran/Phellinus linteus mycelium (fermentation) bioconverted product polysaccharide fraction powder
OBJECTIVES: The sarcopenia (SI) index, defined as the serum creatinine to cystatin C ratio, is considered a predictor of poor muscle health and malnutrition, which is related to major adverse cardiovascular events. However, the effect of the SI index on cognitive function in stroke patients remains unknown. In this study, we aimed to examine the association between the SI and longitudinal cognitive impairment in patients with acute ischemic stroke or transient ischemic attack.
RESEARCH DESIGN AND METHODS: Participants who met the inclusion criteria in this national, multicenter, prospective cohort study were enrolled from the Impairment of Cognition and Sleep (ICONS) study of the China National Stroke Registry-3 (CNSR-3). They were categorized into four groups according to the quartile of the SI index. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale. Multivariable-adjusted logistic regression models were performed to evaluate the association between the SI index and post-stroke cognitive impairment (PSCI) at the 3-month follow-up. Moreover, discrimination tests were used to evaluate the incremental predictive value of the SI index beyond the potential risk factors. Furthermore, we performed subgroup analyses to test interactions.
RESULTS: Among the enrolled participants, the lower the SI index was, the worse the cognitive performance. At the 3-month follow-up, participants in the lowest SI quartile group exhibited a 42% increase in the risk of cognitive impairment relative to the highest quartile group [OR 0.58 (95% CI 0.37-0.90)]. Moreover, after applying the discrimination test, adding the SI index into the potential risk factors resulted in a slight improvement in predicting the risk of cognitive impairment [NRI 14% (P = 0.01)].
CONCLUSION: This study demonstrated that a lower sarcopenia index was positively associated with a higher prevalence of PSCI. Monitoring the SI index in stroke patients and early identification and treatment of individuals with low SI level may be helpful to reduce the risk of cognitive impairment.
The average worldwide prevalence of neural tube defects (NTDs) is 1.0 per 1000 births. Its development is multifactorial due to genetic and non-genetic factors. Spina bifida (SB) is one of main representatives of NTD. The spinal cord lesion level is the main determinant of the level of paralysis, numbness, and difficulties with bladder/bowel functions. Myelomeningocele prenatal repair reduces hydrocephalus and hindbrain herniation and improves motor function. The severity of hydrocephalus is associated with poorer neurodevelopmental outcomes whether operated on prenatally or after birth. People with SB tend to have a lower IQ and cognitive difficulties. Early diagnosis, proactivity, and lifelong multidisciplinary follow-up are key protective issues. Invasive urological interventions should be considered in selected patients after failure of conservative treatment. Transition to adult care should be well planned as it is challenging. Health literacy is directly associated with success at transition. Sexuality and fertility should be addressed before/during puberty. Overall, the rates of fecal and urinary continence and skin breakdown increase with age, whereas the ability to ambulate declines with age. Bowel and urinary incontinence are independent predictors of lower health-related quality of life (HRQoL) in adults with SB. Bowel incontinence has negative impact on HRQoL regardless of frequency or amount. Long-term caregiver support should be offered at diagnosis. Survival at a mean of 50 years is poor, at 32%, due to central nervous system deaths, cancer, urological disease, and sepsis. Challenges to implementation of recommended practices exist, especially in low and middle-income countries.
This population pharmacokinetics (PopPK) analysis of eptinezumab used data from a paediatric study and a prior adult PopPK model to compare eptinezumab pharmacokinetics between adult and paediatric populations to determine dose recommendations for the phase 3 paediatric studies in migraine. The data consisted of 16 adolescents and 12 children with migraine, with corresponding demographics and 278 plasma concentrations in total. PopPK analysis was performed through nonlinear mixed effect modelling and with prior knowledge taken from a previous PopPK model in adults. A two-compartment model-adjusted for body weight impact on clearances and volumes of distributions and scaled to the power of 0.75 and 1.0, respectively-was found to adequately describe the paediatric pharmacokinetic data. The simulated population showed overlap in area under the plasma concentration-time curve and maximum plasma concentration between the paediatric and adult populations, with paediatric exposures within 10%-15% above adult levels on average. To provide comparable exposure to the approved adult doses, weight-based dosing adjustments are recommended for paediatric patients weighing ≤40 kg, while no adjustments are needed for patients weighing >40 kg. These results support the dosing strategy being used in the ongoing efficacy and safety studies with eptinezumab in children and adolescents with migraine.
PURPOSE:The titled pharmaceutical consisting of chondroitin sulfate, or a salt thereof, lecithin and protein, and having angifatigue action, protecting action on gastric mucosa and improving action on constipation. CONSTITUTION:A health promoting and keeping agent containing 1-40pts.wt. chondroitin sulfate or a salt thereof, 0.5-20pts.wt. lecithin and 40-98.5pts.wt. protein and if desired <=10pts.wt., based on 100pts.wt. total weight of main components, vitamin, vegetable extract, e.g. ginseng extract, various amino acids, various minerals, etc. The dosage form is solution, granule, table, troche or capsule, etc. The dose thereof is 1-2g at a time, and administered 1-3 times a day. The agent is widely applied to maintenance of physical strength, fatigue recovery, unpleasant feeling in the gastric and hypogastric regions, menopausal disorder, drunken sickness, nourishment and tonicity, weak physical constitution, etc.
The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.
This project is a two-arm randomized controlled trial evaluating the effects of e-bibliotherapy on improving the psychological well-being of informal caregivers of people with dementia. One hundred and ninety-two informal caregivers of people with dementia will be recruited. Participants in the intervention group will receive eight weekly e-bibliotherapy sessions. The control group will get access to the same e-bibliotherapy app but accept only general daily living knowledge. Psychological well-being, caregiving appraisal, mental health, biomarker of stress, and health-related quality of life will be measured to test the effects of e-bibliotherapy immediately post-intervention, three months post-intervention, and six months post-intervention. Focus group interviews will be conducted immediately post-intervention to explore caregivers' experiences participating in this study.
PURPOSE:To obtain the granular volatile material excellent in sustained releasability and handleability and to facilitate the preservation in other vessels and the use in a container by forming the material with a volatile material which is volatilized with time at normal temps. and the powdery activated carbon coating the material. CONSTITUTION:This granular volatile material is formed with a volatile material which is volatilized with time at normal temps. and the powdery activated carbon coating the material. The activated carbon reduces the exposed region of the volatile material, adsorbs and preserves the volatile material by its adsorptivity, forms a cicle of the volatile material on the entire surface of the granular body and liberates a part of the volatile material from the circle. When the activated carbon is capable of being directly bonded to the material, the coated body is obtained by the powder bed process as the one for producing a microcapsule.
Glial fibrillary acidic protein (GFAP), an intracellular type III intermediate filament protein, provides structural support and maintains the mechanical integrity of astrocytes. It is predominantly found in the astrocytes which are the most abundant subtypes of glial cells in the brain and spinal cord. As a marker protein of astrocytes, GFAP may exert a variety of physiological effects in neurological diseases. For example, previous published literatures showed that autoimmune GFAP astrocytopathy is an inflammatory disease of the central nervous system (CNS). Moreover, the studies of GFAP in brain tumors mainly focus on the predictive value of tumor volume. Furthermore, using biomarkers in the early setting will lead to a simplified and standardized way to estimate the poor outcome in traumatic brain injury (TBI) and ischemic stroke. Recently, observational studies revealed that cerebrospinal fluid (CSF) GFAP, as a valuable potential diagnostic biomarker for neurosyphilis, had a sensitivity of 76.60% and specificity of 85.56%. The reason plasma GFAP could serve as a promising biomarker for diagnosis and prediction of Alzheimer's disease (AD) is that it effectively distinguished AD dementia from multiple neurodegenerative diseases and predicted the individual risk of AD progression. In addition, GFAP can be helpful in differentiating relapsing-remitting multiple sclerosis (RRMS) versus progressive MS (PMS). This review article aims to provide an overview of GFAP in the prediction of clinical progression in neuroinflammation, brain tumors, TBI, ischemic stroke, genetic disorders, neurodegeneration and other diseases in the CNS and to explore the potential therapeutic methods.
PURPOSE:An antitumor agent having reducing action on tumor, containing 2-amino-3-ethoxycarbonyl-6-benzyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyri dine hydrochloride as an active ingredient. CONSTITUTION:An antitumor agent containing a compound shown by the formu la (R1 and R2 are H, or CH3) as an active ingredient. The compound is well- known as a substance having partially anti-inflammatory action, has effects on reduction in number of tomor cells, prolongation of life, inhibition of tomor multiplication, etc. in human tumor, and is useful as an antitumor agent. It is administered orally or parenterally, and parenteral administration includes injection, rectum administration, application, etc. A dose is generally 0.1-1,000 mg/kg/day, preferably 1-500mg/kg/day, and administrated twice-4 times dividedly in case of human.
Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
On the basis of the control group, whey protein powder was given to supplement for 12 weeks.60 grams of protein per day is taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.